肺癌的靶向治疗

Target therapy in lung cancer

20世纪90年代以来,随着人们对肺癌驱动基因的认识,相应的靶向治疗研究也不断深入,以肿瘤分子特点为基础的个体化治疗越来越受重视。表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKIs）是最早进入临床应用的靶向治疗药物,

Epidermal growth factor receptor tyrosine kinase inhibitors（EGFR-TKIs）,as a standard target therapy in lung cancer,has been developed as a chemotherapy drug.Many clinical trials with EGFRTKIs as third line,second line and first line treatment for lung cancer patients were carried out.Only EGFR gene mutations could predict benefit from EGFR-TKIs treatment for patients with lung cancer.Based on the experiences from the development of EGFR-TKIs,Crizotinib（Xalkori,Pfizer） is quickly approved for treatment in some patients with non-small cell lung carcinoma（NSCLC） harboring ALK gene rearrangement in every line.We believe that many other target drugs would be used in clinical practice to treat lung cancer patients.Identification of driver mutations in tumor specimens from Chinese patients is very important.Basic research and drug development in China will be promoted from the discovery of new driver mutations,especially in squamous cell lung cancer and small cell lung cancer.Based on the results of driver mutations tests,Chinese patients will be benefited from global research findings.